Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ856856,50,18
KB766,57670,46
PKN58,3758,38-4,11
Msft438,47438,91,82
Nokia3,7933,7970,44
IBM216,4216,70,82
Mercedes-Benz Group AG59,3459,353,00
PFE29,9329,950,64
19.09.2024 11:53:46
Indexy online
AD Index online
select
AD Index online
 

  • 19.09.2024 11:28:06
PureTech Health (London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
1,47 1,96 0,03 18 755
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiPuretech Health PLC
TickerPRTC
Kmenové akcie:Ordinary Shares
RICPRTC.L
ISINGB00BY2Z0H74
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 90
Akcie v oběhu k 30.06.2024 239 404 190
MěnaUSD
Kontaktní informace
Ulice6 Tide Street, Suite 400
MěstoBOSTON
PSČ02210
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 174 822 333
Fax16174823337

Business Summary: PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Puretech Health PLC revenues decreased 91% to $288K. Net loss applicable to common stockholders increased 67% to $41.8M. Revenues reflect Controlled Founded En segment decrease from $750K to $0K, Internal segment decrease of 57% to $288K. Higher net loss reflects Gain/(loss) on deconsolidation ofsubsidi decrease from $61.8M (income) to $0K, royalties increase from $3.7M to $10.6M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, DirectorEric Elenko-09.04.2024
Chief Executive Officer, DirectorBharatt Chowrira5909.04.2024
Co-Founder, Non-Executive DirectorRobert Langer-
General Counsel, Company SecretaryCharles Sherwood7625.04.202425.04.2024
Chief Portfolio OfficerRobert Lyne-01.01.2023